Comparisons
Research Peptide Comparisons
Each comparison puts two research compounds side by side in a single table: sequence and length, CAS number, molecular weight, receptor target, half-life, and how much published evidence stands behind each one. Where the literature is thin or absent for a compound, the table says so rather than implying equivalence. All compounds are described for in-vitro laboratory research use only.
Featured comparison
Retatrutide vs Tirzepatide
Retatrutide vs Tirzepatide: triple GLP-1/GIP/glucagon agonism against dual GLP-1/GIP. The glucagon arm, CAS and mass data, half-lives, and the phase 2 versus phase 3 evidence gap.
View comparison
Tesamorelin vs CJC-1295 (No DAC)
Tesamorelin vs CJC-1295 (No DAC): 44-residue GHRH analog with phase 3 human data versus a 29-residue fragment with none. CAS, formula, half-life, evidence gaps.
Compound comparisonIpamorelin vs Tesamorelin
Ipamorelin vs Tesamorelin: a 711.9 Da GHSR-1a pentapeptide against a 5,136 Da GHRH analog. Receptor targets, CAS, formula, and the trial-evidence gap between them.
Compound comparisonRetatrutide vs Semaglutide
Retatrutide vs Semaglutide: triple GLP-1/GIP/glucagon agonism against single GLP-1 agonism. CAS, molecular weight, half-life, trial stage. Semaglutide is not stocked.
Compound comparisonBPC-157 vs TB-500
BPC-157 vs TB-500: a 1,419.5 Da gastric pentadecapeptide against synthetic Thymosin β-4. Mechanisms, CAS, formula, the TB-500 naming ambiguity, and what the evidence does not show.
Compound comparisonCJC-1295 (No DAC) vs Ipamorelin
CJC-1295 (No DAC) vs Ipamorelin: GHRH-receptor analog versus GHSR-1a agonist. Why they are blended rather than substituted, plus CAS, formula, mass and evidence limits.
Compound comparisonKLOW Blend vs GLOW Blend
The difference between GLOW and KLOW: KLOW adds KPV to GLOW's GHK-Cu, BPC-157 and TB-500. Side-by-side composition, CAS numbers and lot CoA. For laboratory research use only.
Compound comparisonRetatrutide vs Tirzepatide
Retatrutide vs Tirzepatide: triple GLP-1/GIP/glucagon agonism against dual GLP-1/GIP. The glucagon arm, CAS and mass data, half-lives, and the phase 2 versus phase 3 evidence gap.
Compound comparisonIpamorelin vs Sermorelin
Ipamorelin vs Sermorelin compared: GHSR-1a ghrelin-receptor agonist versus GHRH-receptor analog. Sequence, half-life. ≥99% purity, CoA. Research use only.
Compound comparisonLiraglutide vs Semaglutide: Identity and Evidence Compared
Semaglutide (4114 Da) is 363 Da heavier than liraglutide (3751 Da). Liraglutide vs semaglutide identity and published evidence, side by side.
Research Use Only. All products listed on Peptide.Express are intended for laboratory research and educational purposes only. Comparison pages describe receptor pharmacology and published evidence for scientific reference. No human or therapeutic use is implied, and no comparison states or implies that either compound is safe or effective in humans.